Evidence supporting the use of: Glycine propionyl-l-carnitine
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Glycine propionyl-L-carnitine (GPLC) is a derivative of L-carnitine, a compound involved in cellular energy metabolism. Its use for supporting or treating congestive heart failure (CHF) is primarily based on the broader body of research into L-carnitine and its esters in cardiovascular disease. Some small clinical studies and meta-analyses have suggested that L-carnitine supplementation may have beneficial effects in CHF patients, such as improving exercise capacity, left ventricular function, and possibly reducing mortality. The proposed mechanism is enhanced mitochondrial energy production in cardiac muscle and improved fatty acid oxidation, which is often impaired in heart failure. Specifically for GPLC, the evidence is more limited. There are a few small studies indicating that GPLC can increase nitric oxide levels and improve endothelial function, which could be beneficial in CHF by promoting vasodilation and improving blood flow. However, direct evidence supporting GPLC’s efficacy in CHF is sparse, and most recommendations are extrapolated from data on L-carnitine or propionyl-L-carnitine (PLC), both of which have shown modest benefits in heart failure patients. Overall, while there is a scientific rationale and some early evidence, the quality and quantity of data—especially for GPLC itself—are limited. Larger, well-controlled studies are needed to firmly establish its role in CHF management. Thus, the evidence base is rated as low to moderate (2/5).

More about Glycine propionyl-l-carnitine
More about Congestive Heart Failure

Products containing Glycine propionyl-l-carnitine

We currently have no products on Caring Sunshine that contain this ingredient.